Clinical Trial Update: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation [Phase 1]

View source ↗

Summary

Phase 1 trial of ipilimumab, ibrutinib, and nivolumab for chronic lymphocytic leukemia and Richter transformation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Richter Syndrome
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Status: WITHDRAWN